Objective To review the influence of 131I therapy on bone mineral density (BMD) in patients with hyperthyroidism.Methods Published articles of prospective randomized controlled study,clinical controlled study or case-control study on BMD change in patients with hyperthyroidism after 131I therapy were selected from PubMed,the Excerpta Media Database (Embase),Cochrane library,Chinese Journal Full-text Database,Wanfang Database,Vip Database and Chinese Biomedical Literature Database.Data from the date of database establishment to October 2015 were all reviewed.The languages were restricted to English and Chinese.Meta-analysis was performed with RevMan 5.3.Results Thirteen trials with a total of 668 hyperthyroidism patients were included.The meta-analysis showed that BMD of the lumbar spine,hip joint,femoral neck and osteocalcin were significantly improved after 131I therapy.The weighted mean difference (WMD) for BMD of the lumbar spine was 0.07 (95％ CI:0.04-0.11),P=0.O00 2;that of the hip joint and the femoral neck was 0.13(95％ CI:0.09-0.16) and 0.05(95％ CI:0.03-0.06),respectively(both P＜0.01).The standardized mean difference (SMD) of osteocalcin was-1.20(95％ CI:-1.43--0.97) with P＜0.01.Furthermore,the improvements were time dependent within the 2 years' follow-up.Conclusions 131I therapy improves the BMD and osteocalcin in patients with hyperthyroidism in a time dependent manner within 2 years' follow-up.

ObjectiveTo measure the expression of T-cell immunoglobulin- and mucin domain-3-containing molecule 3 (TIM-3) on CD8+ T cells in peripheral blood mononuclear cells (PBMCs) among patients with chronic hepatitis B (CHB) and to investigate the effect of common gamma-chain cytokines on the expression of TIM-3 on CD8+ T cells in these patients. MethodsFifteen previously untreated patients with CHB who visited the Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, from January to May, 2014, as well as 8 healthy controls, were included in the study. Blood was collected from these subjects, and PBMCs were isolated from blood by Ficoll density gradient centrifugation. PBMCs were separately stimulated with gamma-chain cytokines, interleukin (IL)2, IL-7, IL-15, and IL-21, and anti-CD3/CD28, and the untreated cells were used as a negative control. After four days of culture, PBMCs were stained with monoclonal antibody. Flow cytometry was used to measure the expression of TIM-3 on CD8+ T cells. Comparison of continuous data was made by independent-samples t test. ResultsCompared with the untreated group, the anti-CD3/CD28, IL-2, IL-15, and IL-7 groups had significantly increased expression of TIM-3 on CD8+ T cells (9.629%±9.916%, P=0000 1; 3.817%±2.694%, P = 0.000 6; 5.772%±4.732%, P = 0.005 4; 3.560%±2.045%, P = 0.030 2), while the IL-21 group had nonsignificantly increased expression of TIM-3 on CD8+ T cells (2.503%±2.117%, P = 0.934 1). ConclusionAnti-CD3/CD28 and gamma-chain cytokines IL-2, IL-7, and IL-15 can effectively upregulate the expression of TIM-3 on CD8+ T cells in patients with CHB. It indicates that the inhibition of them can not only reduce the expression of TIM-3, but also may enhance the killing function of CD8+ T cells in patients with CHB.